The Memory Disorders Program is conducting the following ongoing clinical trials. These trials are underway and are no longer recruiting:

Status Title Sponsor
Ongoing Continued Safety Monitoring of Solanezumab in Alzheimer's Disease (EXPEDITION EXT) Eli Lilly & Co.
Ongoing Alzheimer's Disease Neuroimaging Initiative 2 ADCS
Ongoing A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects with Prodromal or Mild AD Biogen Idec
Ongoing Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo (EXPEDITION 3) Eli Lilly & Co.
Ongoing Therapeutic effects of intranasally-administered insulin (INI) in adults with amnestic mild cognitive impairment (aMCI) or mild Alzheimer’s disease (AD) ATRI
Ongoing
Acadia
Ongoing
ADCS and Eli Lilly and Company
Ongoing
Eli Lilly & Company
Ongoing
Hoffmann-La Roche
Ongoing
Biogen MA Inc.
Ongoing
Georgetown University
Ongoing
Genentech

A list of research studies that are Recruiting is also available.